TL;DR
This study introduces a novel approach using Dynamic Network Biomarkers (DNBs) to understand the complex, dynamic shifts in Traditional Chinese Medicine (TCM) syndromes associated with Chronic Hepatitis B (CHB). By identifying a critical transition point and key molecular players (PLG and F12), the research offers a scientific basis for TCM syndrome diagnosis and suggests potential new biomarkers for CHB management.
What Problem Does This Paper Address?
Traditional Chinese Medicine (TCM) utilizes "syndromes" (ZHENG) to classify disease states and guide treatment, but the underlying biological mechanisms of these syndromes, especially their dynamic changes during disease progression, remain poorly understood. Chronic Hepatitis B (CHB) is a global health issue where TCM treatments show promise, but the lack of a scientific basis for TCM syndromes hinders objective assessment and personalized treatment. Existing research often focuses on static differences between syndromes, neglecting the crucial aspect of how these syndromes evolve over time. This paper aims to bridge this gap by applying a systems biology approach to unravel the dynamic molecular mechanisms driving TCM syndrome transitions in CHB.
Methods
The researchers employed a Dynamic Network Biomarker (DNB) method, a statistical model designed to identify critical transition points in complex systems by analyzing molecular fluctuations and correlations. This approach differs from traditional biomarker discovery, which typically focuses on static differences in individual molecules.
The DNB analysis involved:
- Data Preparation: Using transcriptomic data from patients with CHB across different TCM syndromes (Healthy, Liver-gallbladder dampness-heat syndrome (LGDHS), Liver-depression spleen-deficiency syndrome (LDSDS), and Liver-kidney yin-deficiency syndrome (LKYDS)).
- DNB Identification: Applying criteria based on high gene fluctuation (coefficient of variation), strong internal correlations within a gene cluster (PCCin), and weak external correlations (PCCout). A "criterion index" (CI) was used to quantify DNBs and pinpoint the critical stage.
- Functional Analysis: Employing Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses to understand the biological roles of identified DNBs and differentially expressed genes (DEGs).
- Validation: Using serum cytokine profiling (ELISA) and proteomic analysis (iTRAQ) to confirm the expression patterns of key molecules identified by the DNB approach.
Datasets
The study utilized transcriptomic data from a total of 244 blood samples collected from Shuguang Hospital, Shanghai University of TCM. Specifically:
- 64 samples for initial microarray detection (16 healthy, 16 LGDHS, 16 LDSDS, 16 LKYDS).
- An additional 57 samples for validation (20 LGDHS, 20 LDSDS, 17 LKYDS).
- Serum samples from 25 LGDHS, 25 LDSDS, and 25 LKYDS for cytokine measurements.
- Proteomic data from 48 samples (12 LGDHS, 12 LDSDS, 12 LKYDS, and 12 healthy) for iTRAQ analysis.
The study did not introduce a new benchmark dataset but rather applied its methodology to existing patient data categorized by TCM syndromes.
Key Insights and Ideas
- The "Tipping Point" of TCM Syndromes: The study identified LDSDS as a critical "tipping point" in the progression of CHB TCM syndromes, marking a transition from excess to deficiency states. This is a significant finding, as it provides a concrete molecular basis for understanding how TCM syndromes evolve.
- Dynamic Network Biomarkers (DNBs) as Early Warning Signals: DNBs, unlike static biomarkers, capture collective molecular fluctuations and correlations, acting as sensitive indicators of impending system changes. The identified DNBs could serve as early-warning signals for the shift in TCM syndromes.
- Cytokine System's Central Role: The cytokine system was found to be consistently involved throughout the TCM syndrome progression, highlighting its crucial role in mediating inflammation, immune response, and tissue damage in CHB.
- PLG and F12 as Potential Diagnostic Markers: Plasminogen (PLG) and coagulation factor XII (F12) were identified as key DNBs that significantly change during TCM syndrome progression. Their ability to differentiate between TCM syndromes, outperforming traditional liver function tests, suggests their potential as auxiliary diagnostic markers for CHB.
Key Results
- Identification of 52 DNBs: The DNB analysis identified a set of 52 genes that collectively signal the critical transition in TCM syndromes.
- LDSDS as the Critical Stage: The study pinpointed the LDSDS stage as the critical transition point, characterized by the highest CI score.
- Cytokine Pathway Enrichment: Functional analysis revealed that differentially expressed genes associated with DNBs were significantly enriched in cytokine-related pathways, including response to cytokine and cytokine-mediated signaling.
- Validation of PLG and F12: Proteomic analysis confirmed that PLG and F12 expression significantly changed during TCM syndrome progression.
- Diagnostic Ability: Receiver Operating Characteristic (ROC) analysis showed that PLG and F12 had good diagnostic ability (AUC: 0.791 and 0.691, respectively) in differentiating between LGDHS and LKYDS, outperforming traditional liver function indexes.
Limitations and Future Work
- Sample Size: While the study involved a substantial number of participants, the authors suggest that further studies with larger sample sizes are needed to solidify the clinical significance of DNB findings.
- Clinical Application: The study highlights the potential of DNBs (PLG and F12) for auxiliary diagnosis, but further clinical validation is required to fully establish their utility in practice.
- Mechanism Elucidation: While the study identifies key molecular players and pathways, deeper investigation into the precise mechanisms by which DNBs regulate DEGs and influence TCM syndrome dynamics could be beneficial.
- Broader TCM Syndromes: The study focused on specific TCM syndromes related to CHB. Future work could explore the application of DNBs to a wider range of TCM syndromes and diseases.
Summary updated